vTv Therapeutics Inc. - (VTVT) News

vTv Therapeutics Inc. - (VTVT): $1.40

-0.04 (-2.78%)

POWR Rating

Component Grades













Filter VTVT News Items

VTVT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VTVT News Highlights

  • For VTVT, its 30 day story count is now at 7.
  • Over the past 19 days, the trend for VTVT's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • RWLK, CAPR and LICY are the most mentioned tickers in articles about VTVT.

Latest VTVT News From Around the Web

Below are the latest news stories about vTv Therapeutics Inc that investors may wish to consider to help them evaluate VTVT as an investment opportunity.

vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported in the placebo arm Start-up activities for Phase 3 program ongoing with trials expected to begin in early 2022 HIGH POINT, N.C., Oct. 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatme

Yahoo | October 12, 2021

Thinking about buying stock in Camber Energy, Rewalk Robotics, vTv Therapeutics, Quantumscape, or Northern Dynasty Minerals?

NEW YORK , Sept. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, RWLK, VTVT, QS, and NAK. Full story available on Benzinga.com

Benzinga | September 27, 2021

Thinking about buying stock in Capricor Therapeutics, vTv Therapeutics, Li-Cycle Holdings, Predictive Oncology, or Rewalk Robotics?

NEW YORK , Sept. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CAPR, VTVT, LICY, POAI, and RWLK. Full story available on Benzinga.com

Benzinga | September 24, 2021

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects

Intrado Digital Media | September 23, 2021

Multiple insiders bought vTv Therapeutics Inc. (NASDAQ:VTVT) stock earlier this year, a positive sign for shareholders

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Yahoo | September 13, 2021

7 Penny Stocks Waiting on the FDA for Rocket Fuel

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks.

Thomas Niel on InvestorPlace | September 9, 2021

Oral Insulin Market Competitive Research And Precise Outlook 2021 To 2025 -Novo Nordisk A/S, Oramed Pharmaceuticals Inc., vTv Therapeutics

The Global Oral Insulin Market Report 2021 provides an in-depth analysis of key players'' strategies, market growth, product demand, growth factors, technological innovations, regional outlook and global dynamics which includes drivers, challenges, and opportunities dominant in the industry. This Market

OpenPR | September 6, 2021

Down 16.1% in 4 Weeks, Here's Why vTv Therapeutics (VTVT) Looks Ripe for a Turnaround

vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | August 17, 2021

vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021, and provided an update on the progress of its clinical programs.

Intrado Digital Media | August 4, 2021

VTv Therapeutics (VTVT) Reports Q2 Loss, Lags Revenue Estimates

vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 85.71% and -99.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 4, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7092 seconds.